Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dr. Reddy's Laboratories made available the audio recording of its earnings call held on May 12, 2026. The call reviewed the company's performance for the quarter ended March 31, 2026, providing insights into its latest financial results.
May 12 2026 23:05:00
Dr Reddys Laboratories Ltd - 500124 - Corporate Action-Board to consider Dividend
Dr. Reddy's Laboratories recommended a final dividend of ₹8 per equity share for FY26. The dividend is subject to shareholder approval at the AGM, with a record date of July 10, 2026.
May 12 2026 17:05:00
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Change in Management
Dr. Reddy's Laboratories has elevated Mr. Sandeep Khandelwal, Global Generics India Head, to Senior Management Personnel, inducting him into the Management Council. Khandelwal significantly grew the India business from Rs.2,300 crore to Rs.7,000 crore.
May 12 2026 17:05:00
Dr Reddys Laboratories Ltd - 500124 - Fixing Of Record Date As July 10, 2026 For The Purpose Of Payment Of Final Dividend For FY 2025-26
Dr. Reddy's Laboratories fixed July 10, 2026, as the record date for its final dividend of ₹8.00 per equity share for FY26. Payment is subject to shareholder approval at the upcoming AGM.
May 12 2026 16:05:00
Dr Reddys Laboratories Ltd - 500124 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 12, 2026
Dr. Reddy's Laboratories reported Q4 FY26 cons. revenue of ₹7,516 cr (down 11.6% YoY) and net profit of ₹220 cr (down 86% YoY). The Board also recommended a final dividend of ₹8 per equity share for FY26.
May 12 2026 16:05:00
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Dr. Reddy's Laboratories management is scheduled to participate in investor group meetings with HSBC in Mumbai from May 14-15, 2026, and with Bank of America in Singapore from May 18-19, 2026. These meetings are part of routine investor engagement.
May 11 2026 21:05:00
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Dr. Reddy's Laboratories received Health Canada approval for its generic Semaglutide Injection, authorizing its commercialization, sale, and distribution in Canada. This marks a significant milestone as it's the first company to obtain such authorization in Canada.
Apr 29 2026 09:04:00
Dr Reddys Laboratories Ltd - 500124 - Board Meeting Intimation For Recommending Final Dividend, If Any, For The Financial Year 2025-26
Dr. Reddy's Laboratories board will consider recommending a final dividend for FY 2025-26. This decision will be made during an upcoming board meeting, following a prior intimation from March 23, 2026.
Apr 16 2026 15:04:00
Read More